On May 8, 2026, a delegation comprising representatives from the Fujian Provincial Department of Industry and Information Technology, the Provincial Health Commission, the Provincial Department of Science and Technology, the Provincial Innovation Research Institute, Fuzhou New Area, and key medical institutions in Fujian visited Shenzhen Cell Valley Biopharmaceutical Group Co., Ltd. The two sides held symposium discussions on clinical research and translational application of emerging biomedical technologies, the construction of public service platforms for cell and gene therapy, hospital-enterprise collaborative innovation, and regional industrial development.

The visiting delegation included Chen Chuanfang, Deputy Director of the Fujian Provincial Department of Industry and Information Technology; Chen Yong, Director of the Science and Education Department of the Provincial Health Commission; Li Lei, Third-Level Research Associate of the Social Development Department of the Provincial Department of Science and Technology; Pan Xiuwen, Party Committee Member and Vice President of the Provincial Innovation Research Institute; Chen Bin, Party Working Committee Member and Deputy Director of the Administrative Committee of Fuzhou New Area, and Deputy Party Secretary of Changle District; as well as responsible leaders from key medical institutions including Fujian Provincial Maternity and Child Health Hospital, Fujian Provincial Hospital, Fujian Medical University Union Hospital, the First Affiliated Hospital of Fujian Medical University, Fujian Children's Hospital, and Fujian Cancer Hospital. Professor Shi Yuanyuan, Chairman and General Manager of Shenzhen Cell Valley Group, together with relevant company executives, participated in the reception.

During the symposium, Professor Shi Yuanyuan delivered a presentation on the "Proposed Plan for the Construction of a Fujian Provincial Public Service Platform for Clinical Translation of Emerging Biomedical Technologies," framed within the context of the implementation of the Regulations on the Administration of Clinical Research and Clinical Translational Application of Emerging Biomedical Technologies (State Council Decree No. 818), and drawing on the Cell Valley Group's practical experience in cell and gene therapy CRO/CDMO services, GMP manufacturing, quality control, clinical research support, cross-hospital services, and regional public service platform development.

The presentation noted that Fujian Province is home to a number of high-level medical institutions with solid clinical research and disciplinary foundations in areas such as oncology, hematological diseases, neurological disorders, pediatric medicine, and maternal and child health. With the implementation of Decree No. 818, the clinical research and translational application of emerging biomedical technologies will enter a more standardized and systematic phase, placing greater demands on manufacturing and quality control, standardized documentation, pre-ethics support, clinical research management, and capacity for result translation.

Shenzhen Cell Valley proposed exploring the establishment of a "Fujian Provincial Public Service Platform for the Manufacture and Quality Control of Emerging Biomedical Technology Products," leveraging the province's medical resources, research foundations, and industrial conditions. The platform would provide public service capabilities in manufacturing processes, quality control, standardized documentation, project selection, joint filings, clinical research coordination, and result translation to key hospitals, research institutes, and industry players across the province, helping Fujian build a standardized, replicable, and sustainable clinical translation service system.

The two sides held in-depth discussions on provincial-level coordination mechanisms, cooperation vehicles with key hospitals, clinical research project selection, national clinical research filing pathways, coordinated support from science and technology programs, platform space guarantees, and industrial uptake. Professor Shi Yuanyuan noted that the development of emerging biomedical technologies requires not only high-level clinical resources to drive it forward but also specialized, scaled, and standardized public technology platforms for support. The Cell Valley Group will actively cooperate with relevant Fujian authorities and key medical institutions to explore a cooperative mechanism integrating hospital-enterprise collaboration, platform support, and result translation, focusing on priority disease areas.

During the exchange, Chen Chuanfang, Deputy Director of the Fujian Provincial Department of Industry and Information Technology, affirmed the Cell Valley Group's technical accumulation, platform development capabilities, and clinical translation service experience in the cell and gene therapy field. He noted that emerging biomedical technologies represent an important direction for the future development of the life and health industry, and that Shenzhen Cell Valley's platform-based capabilities in GMP manufacturing, quality control, clinical research support, and result translation are highly aligned with Fujian's goals of promoting high-quality development in the biopharmaceutical sector. He expressed hope that both sides would strengthen communication to explore a cooperation pathway that is practical, actionable, and sustainable for Fujian.

Representatives of the participating medical institutions also recognized Shenzhen Cell Valley's capabilities in cell therapy product manufacturing, quality control systems, clinical research services, and multi-center collaboration. They agreed that in the context of Decree No. 818, hospitals conducting clinical research and translational application of emerging biomedical technologies face higher requirements for standardized manufacturing, full-process quality control, standardized documentation systems, and specialized platform support. The Cell Valley's public service platform model could help reduce duplicate construction costs for hospitals and improve the standardized implementation of projects.

Responsible officials from Fujian's health, science and technology, innovation research, and Fuzhou New Area agencies noted during the exchanges that Fujian possesses favorable clinical resources, research foundations, and industrial carrying capacity. Future efforts could focus on deepening communication around policy alignment, project selection, hospital collaboration, platform development, and result translation, promoting efficient coordination among clinical, innovation, and industrial resources.

This visit and exchange laid a solid foundation for mutual understanding of resource bases, cooperation needs, and development concepts. The parties will continue further engagement on collaboration with key hospitals, selection of initial demonstration projects, and platform function development, jointly exploring new pathways for the standardized clinical research and translational application of emerging biomedical technologies.